# US 2023/0142981 A1 · Method for identifing a marker for a biological interaction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0142981 A1
- Document ID: US20230142981A1
- Status: Published application
- Kind: A1
- Application number: 18/150,752
- Filed: 2023-01-05
- Published: 2023-05-11
- Earliest claimed: 2020-07-06
- Assignees: Arpeggio Biosciences, Inc.
- Applicants: Arpeggio Biosciences, Inc.
- Inventors: Timothy READ; Joseph AZOFEIFA; Maria LAI; Joel BASKEN
- Web page: https://patentgrep.com/patent/US20230142981A1

## CPC

- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/26: involving oxidoreductase
- C12Q 1/68: involving nucleic acids
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C40B 30/06: by measuring effects on living organisms, tissues or cells
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5023: {on expression patterns}
- G01N 33/5044: {involving specific cell types}
- C12Q 1/6851: Quantitative amplification
- C12Q 2539/10: The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2333/902: Oxidoreductases (1.)
- G01N 2500/10: involving cells
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods of identifying a marker for a biological interaction, the method comprising: quantifying genome-wide RNA expression in cells; exposing the cells to a perturbagen for a period of time sufficient to induce the biological interaction in the cells, wherein the induced biological interaction comprises inducing changes in RNA expression in the cells that are exposed to the perturbagen; quantifying genome-wide nascent RNA expression in the cells that were exposed to the perturbagen; calculating a difference in the genome-wide nascent RNA expression between (i) the genome-wide RNA expression in the cells absent the perturbagen and (ii) the genome-wide nascent RNA expression in the cells that were exposed to the perturbagen; and identifying the marker using the calculated difference in the genome-wide nascent RNA expression.

## Claims

### Claim 1

A method of identifying a marker for a biological interaction, the method comprising:
a. quantifying genome-wide RNA expression in cells;
b. exposing the cells to a perturbagen for a period of time sufficient to induce the biological interaction in the cells, wherein the induced biological interaction comprises inducing changes in RNA expression in the cells that are exposed to the perturbagen;
c. quantifying genome-wide nascent RNA expression in the cells from (b) that were exposed to the perturbagen;
d. calculating a difference in the genome-wide nascent RNA expression between:
i. the genome-wide RNA expression in the cells from (a) absent the perturbagen; and
ii. the genome-wide nascent RNA expression in the cells from (c) that were exposed to the perturbagen; and
e. identifying the marker using the calculated difference in the genome-wide nascent RNA expression.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological interaction induced by the perturbagen comprises an existing biological interaction in the cells from (a).

### Claim 3 (depends on 1)

The method of claim 1, wherein the exposing the cells to the perturbagen comprises in vitro exposure, in vivo exposure, or ex vivo exposure in an animal model.

### Claim 4 (depends on 1)

The method of claim 1, wherein the period of time sufficient to induce the biological interaction from the cells comprises about 60 minutes or less, about 30 minutes or less, about 15 minutes or less, or about 5 minutes or less.

### Claim 5 (depends on 4)

The method of claim 4, wherein the period of time sufficient to induce the biological interaction from the cells comprises a series of exposure times.

### Claim 6 (depends on 5)

The method of claim 5, wherein the series of exposure times is performed in less than about 5 minutes, less than about 15 minutes, less than about 1 hour, less than about 6 hours, or less than about 24 hours.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cells comprise cancer cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cells comprise a ferroptosis-sensitive cancer cell line.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cells comprise two or more different cell lines.

### Claim 10 (depends on 1)

The method of claim 1, wherein the perturbagen comprises two or more perturbagens selected to induce the biological interaction.

### Claim 11 (depends on 1)

The method of claim 1, wherein the marker comprises a single RNA.

### Claim 12 (depends on 1)

The method of claim 1, wherein the marker comprises two or more different RNAs.

### Claim 13 (depends on 1)

The method of claim 1, wherein the marker comprises two or more types of RNAs.

### Claim 14 (depends on 1)

The method of claim 1, wherein the marker comprises an enhancer RNA.

### Claim 15 (depends on 1)

The method of claim 1, wherein the marker is any expressed RNA for which the difference in (d) is a statistical outlier relative to the difference in the genome-wide nascent RNA expression of a nearest RNA of the cells.

### Claim 16 (depends on 15)

The method of claim 15, wherein the statistical outlier comprises an expressed RNA at least 1.5 standard deviations from the nearest RNA.

### Claim 17 (depends on 15)

The method of claim 15, wherein the statistical outlier comprises an expressed RNA at least 2 standard deviations from the nearest RNA.

### Claim 18 (depends on 15)

The method of claim 15, wherein the statistical outlier comprises an expressed RNA at least 2.5 standard deviations from the nearest RNA.

### Claim 19 (depends on 15)

The method of claim 15, wherein the statistical outlier comprises an expressed RNA at least 3 standard deviations from the nearest RNA.

### Claim 20 (depends on 1)

The method of claim 1, further comprising quantifying a dose dependent response of the cells to the perturbagen.
